Reports Q1 revenue $5.58M, consensus $5.5M. “We are excited about our strong start to 2025, a year we expect to be rich in potential catalysts,” said Dr. Shantanu Gaur, founder and CEO. “Our financial results reflect increased efficiency as we move toward profitability, with expenses continuing to reduce, gross margin expanding, and operating loss narrowing. After completing our pre-PMA meeting with FDA, where we discussed our topline results from our AUDACITY trial, we expect to complete our PMA submission on schedule.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALUR:
- Allurion Technologies up 58% at $3.78 after abstract data presentation
- Allurion Technologies announces presentation of four abstracts at ECO
- Allurion Technologies files to sell 6.18M shares of common stock for holders
- Allurion Technologies’ Earnings Call: Growth Amid Challenges
- 3 Best Stocks to Buy Now, 3/28/2025, According to Top Analysts